Engineered M13 Nanofiber Accelerates Ischemic Neovascularization by Enhancing Endothelial Progenitor Cells.
10.1007/s13770-017-0074-x
- Author:
Jun Hee LEE
1
;
Sung Wook KIM
;
Seung Taek JI
;
Yeon Ju KIM
;
Woong Bi JANG
;
Jin Woo OH
;
Jaeho KIM
;
So Young YOO
;
Sang Hong BEAK
;
Sang Mo KWON
Author Information
1. Department of Pharmacology and Toxicology, University of Alabama at Birmingham School of Medicine, Birmingham, AL 35294, USA.
- Publication Type:Original Article
- Keywords:
M13 bacteriophage;
Endothelial progenitor cell;
RGD;
SDKP;
Neovascularization
- MeSH:
Animals;
Bacteriophages;
Blood Vessels;
Catalytic Domain;
Cell Death;
Endothelial Progenitor Cells*;
Hindlimb;
Ischemia;
Nanofibers*;
Regeneration;
Stem Cells;
Thymosin
- From:
Tissue Engineering and Regenerative Medicine
2017;14(6):787-802
- CountryRepublic of Korea
- Language:English
-
Abstract:
Dysfunction or loss of blood vessel causes several ischemic diseases. Although endothelial progenitor cells (EPCs) are a promising source for cell-based therapy, ischemia-induced pathophysiological condition limits the recovery rate by causing drastic cell death. To overcome this issue, we attempted to develop a cell-targeted peptide delivery and priming system to enhance EPCbased neovascularization using an engineered M13 bacteriophage harboring nanofibrous tubes displaying ∼ 2700 multiple functional motifs. The M13 nanofiber was modified by displaying RGD, which is an integrin-docking peptide, on the minor coat protein, and bymutilayering SDKPmotifs,which are the key active sites for thymosin b4, on themajor coat protein. The engineered M13 nanofiber dramatically enhanced ischemic neovascularization by activating intracellular and extracellular processes such as proliferation, migration, and tube formation in the EPCs. Furthermore, transplantation of the primed EPCs with the M13 nanofiber harboring RGD and SDKP facilitated functional recovery and neovascularization in a murine hindlimb ischemia model. Overall, this study demonstrates the effectiveness of theM13 nanofiber-based novel peptide deliveryandprimingstrategy inpromotingEPC bioactivity and neovessel regeneration. To our knowledge, this is first report onM13 nanofibers harboring dual functional motifs, the use of which might be a novel strategy for stem and progenitor cell therapy against cardiovascular ischemic diseases.
